RecruitingNCT06400121
Apimostinel or placebo with cognitive training for depression
About this title
Read the official source — NCT06400121Medication studyAges 18–60United States
Understand this study
Who could participate?
Listed age limits: 18 years to 60 years.
- Listed locations
- PittsburghSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 28, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 150
- Sponsor
- Rebecca Price
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Psychotherapy / behavioral intervention, Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT06400121
- Official title
Show the full official title
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single Intravenous Dose, Parallel Efficacy Study of Apimostinel With or Without Subsequent Automated Self-Association Training in Subjects With Major Depressive Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Pittsburgh
Questions about this study
Who is behind this study?
The study sponsor is Rebecca Price.
Does this study involve medication?
Yes. The study involves medication, including Apimostinel Infusion, Intravenous and Isotonic Solution, Intravenous.
Who can participate?
Listed age limits: 18 years to 60 years.
Is this study still recruiting?
The registry lists this study as recruiting.
